Thrombolysis with a combination of small doses of streptokinase and full doses of heparin

Some of the possible advantages of combined treatment with heparin and thrombolytic drugs are real, while others are potential, and remain to be demonstrated. The most apparent advantage of combined treatment over the use of thrombolytic drugs alone is the reduced cost of treatment, a particularly important consideration with urokinase. A potential advantage is the possibility that further thromboembolic episodes during treatment may be less likely to occur than with present schedules of thrombolytic therapy. A disadvantage of the combined treatment regimen used by us is that more complex laboratory control is needed to monitor treatment than when high dose streptokinase is used.